[Studies on antinephritic effect of lipo PGE1 (1). Effect of lipo PGE1 on crescentic-type anti-GBM nephritis in rats].
The present study was designed to examine the anti-nephritis effect of Lipo PGE1 on crescentic-type anti-glomerular basement membrane (anti-GBM) nephritis in rats. Lipo PGE1, given i.v. twice a day at 20-80 g/kg from the day after the anti-GBM serum injection (the 1st day), remarkably inhibited the urinary protein excretion as wall as glomerular histopathological changes such as crescent formation, adhesion of capillary walls to Bowman's capsule, and fibrinoid necrosis. Lipo PGE1 at doses, which the anti-nephritic action was recognized, significantly inhibited the elevation of platelet aggregation in renal vein and the decrease of renal blood flow. In addition, Lipo PGE1 significantly inhibited the elevation of plasma antibody titer against rabbit gamma-globulin the apparently reduced the deposition of rat IgG in glomeruli. These results suggest that intravenous Lipo PGE1 may be useful for the treatment of rapidly progressive glomerulonephritis and this agent may mainly exert the anti-nephritic action by reducing the deposition of immune complex in glomeruli via the suppression of host antibody formation. Furthermore, the inhibition of platelet aggregation and the increase in renal blood flow by Lipo PGE1 may be also in part related to the anti-nephritic action of this agent.
Nagao
T
T
Department of Pharmacology, Faculty of Pharmacy, Meijo University.
Hattori
T
T
Ito
M
M
Suzuki
Y
Y
D000527:Alprostadil / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D005921:Glomerulonephritis / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012079:Renal Circulation
D010975:Platelet Aggregation Inhibitors; D000527:Alprostadil